Other News To Note
Monday, September 19, 2011
Cempra Pharmaceuticals Inc., of Chapel Hill, N.C., presented abstracts showing that its antibiotic candidate CEM-101 can be given intravenously without pain in a rabbit ear vein model and provide evidence that inhibition of nicotinic acetylcholine receptors may account for some adverse events associated with telithromycin.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.